Patents
Literature
11 results about "Arenavirus" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
An arenavirus is a negative-sense, single-stranded RNA virus that is a member of the family Arenaviridae. These viruses infect rodents and occasionally humans; arenaviruses have also been discovered which infect snakes. At least eight arenaviruses are known to cause human disease. The diseases derived from arenaviruses range in severity. Aseptic meningitis, a severe human disease that causes inflammation covering the brain and spinal cord, can arise from the lymphocytic choriomeningitis virus (LCMV) infection. Hemorrhagic fever syndromes, including Lassa fever, are derived from infections such as Guanarito virus (GTOV), Junin virus (JUNV), Lassa virus (LASV), Lujo virus (LUJV), Machupo virus (MACV), Sabia virus (SABV), or Whitewater Arroyo virus (WWAV). Arenaviruses are divided into two groups: the Old World and the New World viruses. The differences between these groups are distinguished geographically and genetically. Because of the epidemiological association with rodents, some arenaviruses and bunyaviruses are designated as roboviruses.
Method for producing an antitumoral arenavirus as well as arenavirus mutants
The invention relates to a mutant of an arenavirus having improved antitumoral properties. The invention also relates to a method of generating such an arenavirus mutant, related pharmaceutical compositions, medical uses, methods of treatment, and isolated proteins and nucleic acids.
Owner:ABALOS THERAPEUTICS GMBH
ARENA REPLICA DEFECTIVE VARIANT
The invention relates to an infectious arenavirus particle that is genetically engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but incapable of producing further infectious progeny particles in normal, non-genetically engineered cells.One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z, and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells, but still allow gene expression in arenavirus vector-infected cells, and foreign genes encoding an antigen or other protein of interest or nucleic acids that regulate host gene expression are expressed under the control of arenavirus promoters, internal ribosome entry sites, or under the control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II, or RNA polymerase III. The modified arenaviruses are useful as vaccines and therapeutic agents for a variety of diseases.
Owner:UNIVERSITY OF ZURICH
Rat kidney cell line and application thereof
PendingCN121674327AViral antigen ingredientsMicrobiological testing/measurementLymphocytic cellTGE VACCINE
The invention belongs to the technical field of virus infection cell lines, and particularly relates to a rats kidney cell line and application thereof. Wherein the preservation number of the kidney cell line of the rats with the yellow chest is CCTCC (China Center For Type Culture Collection) NO: C2025271. The rats kidney cell line (RtK-15W) provided by the invention has multiple advantages of high sensitivity, high replication efficiency, quantitative detection, passage stability and the like on arenavirus; a reliable cell tool and an efficient, reliable and generalizable experimental platform are provided for separation and identification, in-vitro amplification, titer determination, pathogenesis research, drug screening, antibody neutralization experiment, vaccine effect evaluation and the like of arenaviruses (including lymphocytic choriomeningitis virus (LCMV) and Wenzhou virus (WENV)).
Owner:WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
Arenavirus formulations, methods and uses thereof
The present disclosure relates to improved liquid and lyophilized arenavirus formulations, as well as pharmaceutical compositions derived therefrom. The disclosure also relates to methods of making such arenavirus formulations, and methods of treating or preventing diseases or conditions (e.g., cancer and infectious diseases) using such arenavirus formulations and pharmaceutical compositions derived therefrom.
Owner:GILEAD SCIENCES INC
Aarenavirus formulations, methods and uses thereof
The present disclosure relates to improved liquid and lyophilized arenavirus formulations, as well as pharmaceutical compositions derived therefrom. The disclosure also relates to methods of making such arenavirus formulations, and methods of treating or preventing diseases or conditions (e.g., cancer and infectious diseases) using such arenavirus formulations and pharmaceutical compositions derived therefrom.
Owner:GILEAD SCIENCES INC
HEPATITIS B VIRUS VACCINATION
The present application provides immunotherapies for hepatitis B virus infections. Provided herein are genetically modified arenavirus vectors suitable as vaccines for preventing and treating hepatitis B virus infections. Also provided herein are pharmaceutical compositions and methods for treating hepatitis B virus infections. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods for treating hepatitis B virus infection.
Owner:HOOKIPA BIOTECH GMBH
Monoclonal antibody and single-chain antibody for resisting arenavirus NP protein as well as construction method and application of monoclonal antibody and single-chain antibody
PendingCN121203009AImmunoglobulins against virusesMicroorganism based processesAntigenSingle-Chain Antibodies
The invention relates to the technical field of biological medicine, and discloses an anti-arenavirus NP protein monoclonal antibody, an anti-arenavirus NP protein single-chain antibody and a construction method and application of the anti-arenavirus NP protein single-chain antibody, the amino acid sequence of a heavy chain variable region of the monoclonal antibody is shown as SEQ ID NO: 1, and the amino acid sequence of a light chain variable region of the monoclonal antibody is shown as SEQ ID NO: 2. The invention provides a novel specific monoclonal antibody, the affinity of the monoclonal antibody to the arenavirus NP protein is strong, the monoclonal antibody can specifically recognize the NP protein and a new isolated strain, and the blank of an efficient antibody for the arenavirus NP protein with an unpublished sequence in the prior art is filled. Based on the sequence of the monoclonal antibody, the invention also designs a single-chain antibody, and the single-chain antibody has good stability and antigen (arenavirus) binding activity.
Owner:HUBEI UNIV
Replication-defective arenavirus vectors
The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III. The modified arenaviruses are useful as vaccines and therapeutic agents for a variety of diseases.
Owner:UNIVERSITY OF ZURICH
Three-fragment arenavirus as vaccine vector
The present application relates to arenavirus having an open reading frame ("ORF") rearrangement in its genome. In particular, described herein are modified arenavirus genomic fragments, where the arenavirus genomic fragments are engineered to carry a viral ORF at a position other than the wild-type position of the ORF. Also described herein are three-fragment arenavirus particles comprising one L fragment and two S fragments, or two L fragments and one S fragment. The arenaviruses described herein may be suitable for vaccines and / or treatment of diseases and / or for immunotherapy.
Owner:UNIVERSITY OF GENEVA
Vaccine against hepatitis b virus
ActiveCN115948467BSsRNA viruses negative-senseAntibody mimetics/scaffoldsHepatitis B immunizationPharmaceutical drug
The present application provides immunotherapy for hepatitis B virus infection. Provided herein are genetically modified arenavirus vectors suitable as vaccines for the prevention and treatment of hepatitis B virus infection. Also provided herein are pharmaceutical compositions and methods for the treatment of hepatitis B virus infection. In particular, provided herein are pharmaceutical compositions, vaccines, and methods of treating hepatitis B virus infection.
Owner:GILEAD SCIENCES INC
Lassavirus vaccines
ActiveUS12558410B2SsRNA viruses negative-senseSsRNA viruses positive-senseViral glycoproteinNucleotide
The present invention relates to polynucleotides comprising a sequence of a live, infectious, attenuated Flavivirus wherein a nucleotide sequence encoding at least a part of a arenavirus glycoprotein protein is located at the intergenic region between the E and NS1 gene of said Flavivirus, such that a chimeric virus is expressed, characterised in that the encoded sequence C terminally of the E protein of said Flavivirus and N terminally of the signal peptide of the NS1 protein of said Flavivirus comprises in the following order: —a further signal peptide of a Flavivirus NS1 protein, —an arenavirus Glycoprotein protein lacking the N terminal signal sequence and the GP2 transmembrane domain, —a TM1 and TM2 domain of a flaviviral E protein.
Owner:KATHOLIEKE UNIV LEUVEN